Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMIX: Neoadjuvant Epirubicin, Docetaxel, and Bevacizumab in Breast Cancer
NCT00957125Phase 2Unknown
- Start
- Sep 2008
- Primary completion
- Nov 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in breast cancer. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00957125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00957125.